<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501173</url>
  </required_header>
  <id_info>
    <org_study_id>CR108454</org_study_id>
    <secondary_id>212082PCR4049</secondary_id>
    <nct_id>NCT03501173</nct_id>
  </id_info>
  <brief_title>A Study of Participants With Advanced Prostate Cancer in Canada</brief_title>
  <acronym>GURC</acronym>
  <official_title>A Multicentre Cohort Study of Patients With Advanced Prostate Cancer in Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to document the course of advanced prostate cancer in Canada in
      terms of disease progression, real-world treatment, and patient management.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Prostate Specific Antigen (PSA) Progression</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Time to PSA progression is defined as the time interval from the date of start of study enrollment to the date of first evidence of PSA progression. In participants whose PSA level has decreased, PSA progression is defined as at least a 25 percent (%) increase from nadir (lowest value including the most recent value prior to study enrollment) and an increase in the absolute value of 2 nanogram per milliliter (ng/mL) or greater, confirmed by a subsequent measurement at least 3 weeks after the increase. In participants whose PSA level has not decreased, PSA progression is defined as at least a 25% increase from the most recent value prior to study enrollment and an increase in the absolute value of 2 ng/mL or greater after 12 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Radiographic Evidence of Disease Progression</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Time to radiographic evidence of disease progression is defined as the time interval from the date of start of study treatment to the date of first appearance of 2 or more new bone lesions on bone scan or enlargement of a soft tissue lesion using the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Skeletal-Related Events</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Time to skeletal-related events is defined as the time interval from the date of start of study treatment to the date of first skeletal-related event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Death</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Time to death is defined as the time interval from the date of start of study enrollment to death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Different Primary Causes of Death</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>The number of participants with different primary causes of death will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Progression from mCSPC to mCRPC in Participants with mCSPC</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>In participants with mCSPC, time to progression from mCSPC to mCRPC is defined as the time interval which is either calculated from date when mCSPC was first documented or from the date of start of study treatment, if participant receives treatment for mCSPC to the progression to mCRPC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from Biochemical Recurrence (BCR) to Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) and nmCRPC to mCRPC</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>In participants with mCRPC, time from BCR to nmCRPC and nmCRPC to mCRPC will be analyzed retrospectively. BCR is defined as PSA greater than (&gt;)0.2 nanogram per milliliter (ng/mL) after radical prostatectomy and PSA &gt;2 ng/mL above the nadir (lowest value including the most recent value prior to study enrollment) after radical radiotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with PSA Testing from BCR to nmCRPC and nmCRPC to mCRPC, in Participants with mCRPC</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>In participants with mCRPC, number of participants having PSA testing from BCR to nmCRPC and nmCRPC to mCRPC will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PSA Level at Start of Androgen Deprivation Therapy (ADT) in Participants with mCRPC</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>In participants with mCRPC, PSA level at start of ADT will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PSA Doubling Time (PSAdt) at the Detection of Castration Resistance in Participants with mCRPC</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>In participants with mCRPC, PSAdt at the detection of castration resistance will be reported. PSAdt is the length of time it takes for a PSA to double based on an exponential growth pattern.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Initiation of Subsequent Prostate Cancer Treatment</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Time to initiation of subsequent prostate cancer treatment is defined as the time interval from the date of start of study treatment to the date of start of subsequent prostate cancer treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Each Therapy</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Duration for each therapy will be reported for all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Chemotherapy, Other Drug Treatments, or no Drug Treatment</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Percentage of participants receiving chemotherapy, other drug treatments, or no drug treatment, will be reported for all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Treatment Initiation</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Time to treatment initiation, will be reported for all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Dose Modification</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Time to dose modification, will be reported for all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Switch the Treatment</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of participants who switch the treatment, will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Discontinued the Treatment</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of participants who discontinued the treatment, will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Most Common Sequences for Lines of Therapy in Participants with mCRPC</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>In participants with mCRPC, most common sequences for lines of therapy will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Retreated with Docetaxel in Participants with mCRPC</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>In participants with mCRPC, number of participants having retreatment with docetaxel will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participant with Radiographic Imaging Modality</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Percentage of participants with radiographic imaging modality which includes bone scan, magnetic resonance imaging, ultrasound, X-ray will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days Hospitalized for Prostate Cancer or Treatment of Prostate Cancer</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of days for which participant was hospitalized for prostate cancer or treatment of prostate cancer, will be reported for all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Visits to Emergency Department for Prostate Cancer or Treatment of Prostate Cancer</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of visits to emergency department for prostate cancer or treatment of prostate cancer, will be reported for all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Outpatient Visits to Specialists Involved in Management of Prostate Cancer</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Number of outpatient visits to specialists (urologist, medical oncologist, uro-oncologist, radiation oncologist) involved in management of prostate cancer, will be reported for all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Charlson Comorbidity Index Score</measure>
    <time_frame>Approximately up to 3 years</time_frame>
    <description>Charlson Comorbidity Index score will be summarized descriptively. The Charlson Comorbidity Index is a 19-item measure assessing comorbid conditions. The total possible score on the Charlson Comorbidity Index ranges from 0 to 37. If a condition is not present, the score for that condition is zero. The higher scores indicate greater comorbidity.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)</arm_group_label>
    <description>Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 3 months, documented metastatic prostate cancer, and no more than 90 days of androgen deprivation therapy (ADT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Castrate-Resistant Prostate Cancer (mCRPC)</arm_group_label>
    <description>Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [&lt;]50 nanogram per deciliter [ng/dL] [&lt;1.7 nano moles per liter{nmol/L}]), and the first treatment for mCRPC was started in the past 3 months or is scheduled to begin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Participants will not receive any intervention in this study. Participants will receive standard of care therapy.</description>
    <arm_group_label>Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)</arm_group_label>
    <arm_group_label>Metastatic Castrate-Resistant Prostate Cancer (mCRPC)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participant having advanced prostate cancer (metastatic castrate-sensitive prostate cancer
        [mCSPC] or metastatic castrate-resistant prostate cancer [mCRPC]) will be enrolled in this
        study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have a confirmed diagnosis of adenocarcinoma of the prostate

          -  Participant must have metastatic prostate cancer, as follows: a) Metastatic
             castrate-sensitive prostate cancer (mCSPC): new mCSPC diagnosis in the past 3 months,
             documented metastatic prostate cancer, no more than 90 days of androgen deprivation
             therapy (ADT), b) Metastatic castrate-resistant prostate cancer (mCRPC): mCRPC
             diagnosis at any time, documented metastatic prostate cancer, documented castration
             resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific
             antigen [PSA] despite testosterone less than [&lt;]50 nanogram per deciliter [ng/dL]
             [&lt;1.7 nano moles per liter{nmol/L}]), the first treatment for mCRPC was started in the
             past 3 months or is scheduled to begin

          -  Participant must have a life expectancy of more than 6 months

          -  Participant must sign (and/or their legally acceptable representative, if applicable)
             a participation agreement/informed consent form (ICF) allowing data collection and
             source data verification in accordance with local requirements and/or sponsor policy

        Exclusion Criteria:

          -  At the time of screening, participant is currently enrolled in an investigational
             clinical study for prostate cancer

          -  Participant is currently enrolled in an observational study sponsored or managed by a
             Janssen company
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prostate Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital / Vancouver Prostate Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver BC</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II - Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research St. Joseph's - Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology South Shore Research</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUM - Centre hospitalier universitaire de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Québec Université Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

